Don't miss this opportunity.
Amarantus Bioscience - AMBS - Currently trading under a dime. Market cap of $50M with five pipeline assets each of which could be worth many times the current M.C.
Strong position in Alzheimer's diagnostics. Patented drug, MANF, already has four orphan indications and one designation.
Zacks' bio-tech analyst Jason Napadano has a buy rating on the stock and believes it's worth almost four times its current valuation.
Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on the company's B.O.D. and believes it could be another Amgen.
Friday's C.E.O.'s blog: Up Listing to national exchange and no additional funding required.
Read the Yahoo news.
Twitter: @AmarantusBio .... 8,540 followers
The company's patented drug, MANF, could offer a potential cure for a myriad of diseases including diabetes.
Most undervalued stock in the market. Buy a few shares before it gaps higher.
AMBS - Currently trading under a dime.
Presenting at the Aegis Conference today. Read the recent Yahoo news.
Expected to announce a deal soon with Becton Dickinson to market its diagnostic test to detect early stage Alzheimer's. Potential $500,000,000 annual market.
The company recently announced an "orphan indication" for its patented MANF drug to treat Retinitis Pigmentosa.
Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on the company's advisory board.
Follow the company on Twitter: @AmarantusBio .... 8,535 followers
Becton Dickinson deal and second orphan indication for MANF are just the beginning.
Buy a few shares under seven cents and hold them for six months.
Becton Dickinson news expected soon.
Posted on July 3rd, 2013 by Laura Fagundes:
Big pharma has contributed to M&A activity in a big way in recent years. In fact, pharma M&A is responsible for 63% of big pharma sales growth between 1995 and 2014, according to an analysis by Datamonitor, which looked at the 22 largest M&A events since 1995.
So, will this M&A trend continue?
Pharma M&A As New Drug Development
The short answer is that this trend will most likely continue. Many pharmaceutical companies continue to see old patents expire and simply don’t have enough new drugs in the pipeline that are earning regulatory approval.
Between 2011 and mid-2014, 50% of the top 10 bestselling drugs will have lost patent protection in the US, according to Celerant Consulting’s Private Equity Centre of Excellence.
That’s forcing these companies to look for other ways to stay competitive and profitable—and many are choosing to purchase startups with promising research or smaller companies that are well established within a specific niche as a way of doing both.
The End of Blockbuster Drugs Leads to More Pharma M&A
Emerging markets offer some of the biggest opportunities for growth these days. These markets are, by nature, not aimed at the masses, instead targeting specific diseases and health issues.
This is essential if big pharma companies hope to compete with generic, low-cost drugs. However it contributes to the growth of pharma M&A in two ways:
First, it is undeniably quicker to acquire an established leader within a specific niche than to create a new department and work to become an established player.
Second, smaller niche drugs mean smaller profits. Without the huge blockbuster drugs that are aimed at common medical problems like high cholesterol, pharma companies are forced to utilize a bigger portfolio to maintain the same profits. That means establishing themselves not just in one or two specific niches, but working to become
The company's patented MANF drug could be worth billions. Recentyly announced "orphan indication" for Retinitis Pigmentosa. A second "orphan indication" will be released soon.
Buy a few shares under a dime. Due diligence.
Follow the company on Twitter: @AmarantusBio .... 8,477 followers.
One of the co-founders of Amgen and the former head of M & A at Novartis are two of the members of the company's advisory board.
News expected before the end of the quarter. Get in today at seven cents.
Most undervalued stock in the market.
MANF could be a major drug in the treatment of T.B.I. The company sponsored the N.F.L. conference on T.B.I. held in Minneapolis in June.
Buy and hold for six months.
One of the co-founders of Amgen and the former head of M & A for Novartis are on the company's advisory board.
Company recently announced an "orphan indication" for Retinitis Pigmentosa for its patented MANF drug. C.E.O. announced at the Rodaman & Renshaw Conference last week that the company now has a second "orphan indication" for MANF.